DK1019060T3 - Androgensynteseinhibitorer - Google Patents

Androgensynteseinhibitorer

Info

Publication number
DK1019060T3
DK1019060T3 DK98903769T DK98903769T DK1019060T3 DK 1019060 T3 DK1019060 T3 DK 1019060T3 DK 98903769 T DK98903769 T DK 98903769T DK 98903769 T DK98903769 T DK 98903769T DK 1019060 T3 DK1019060 T3 DK 1019060T3
Authority
DK
Denmark
Prior art keywords
prostate cancer
present
benign prostatic
prostatic hypertrophy
androgen
Prior art date
Application number
DK98903769T
Other languages
Danish (da)
English (en)
Inventor
Yangzhi Ling
Angela Brodie
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1019060T3 publication Critical patent/DK1019060T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98903769T 1997-02-05 1998-02-05 Androgensynteseinhibitorer DK1019060T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/795,932 US5994334A (en) 1997-02-05 1997-02-05 Androgen synthesis inhibitors
PCT/US1998/001569 WO1998033506A1 (en) 1997-02-05 1998-02-05 Androgen synthesis inhibitors

Publications (1)

Publication Number Publication Date
DK1019060T3 true DK1019060T3 (da) 2007-11-12

Family

ID=25166812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98903769T DK1019060T3 (da) 1997-02-05 1998-02-05 Androgensynteseinhibitorer

Country Status (11)

Country Link
US (2) US5994334A (de)
EP (1) EP1019060B1 (de)
JP (2) JP5043250B2 (de)
AT (1) ATE368466T1 (de)
AU (1) AU6045398A (de)
CA (2) CA2628607C (de)
DE (1) DE69838177T2 (de)
DK (1) DK1019060T3 (de)
ES (1) ES2290984T3 (de)
PT (1) PT1019060E (de)
WO (1) WO1998033506A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
WO2001005364A1 (en) * 1999-07-15 2001-01-25 The Procter & Gamble Company Nitrogen-containing steroid compounds and their use to regulate hair growth
US6093421A (en) * 1999-08-31 2000-07-25 Biotics Research Corporation Maca and antler for augmenting testosterone levels
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
WO2002000681A1 (en) * 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
US6413951B2 (en) 2000-06-27 2002-07-02 Aventis Pharmaceuticals, Inc. 20-fluoro-17(20)-vinyl steroids
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2004097002A2 (en) * 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
SI1781683T1 (sl) 2004-08-24 2012-06-29 Btg Int Ltd Postopek za pripravo 17-vinil-triflatov kot intermediatov
EP1853266B1 (de) * 2005-01-10 2011-10-12 Cortendo AB (publ) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
RU2009116632A (ru) * 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
EP2167090A4 (de) 2007-06-06 2010-08-25 Univ Maryland Hdac-inhibitoren und auf hormone zielende arzneimittel zur krebsbehandlung
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
EP2188301B9 (de) * 2007-08-24 2014-03-05 Council of Scientific & Industrial Research Neue steroidale ester von 17-oximino-5-androsten-3-beta-ol
EP2194962A2 (de) * 2007-09-17 2010-06-16 Human Pheromone Sciences, Inc. Duftstoffzusammensetzungen und andere zusammensetzungen mit natürlich vorkommenden stoffen aus korallen
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US7923426B2 (en) 2008-06-04 2011-04-12 The Procter & Gamble Company Detergent composition
EP2135933B1 (de) 2008-06-20 2013-04-03 The Procter and Gamble Company Waschzusammensetzung
WO2010065936A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR20120068026A (ko) 2009-09-11 2012-06-26 바이오네이처 이.에이. 리미티드 염증 및 자가면역 질환에 대한 스테로이드 화합물의 용도
EP2506855A4 (de) * 2009-11-30 2014-07-30 Harbor Biosciences Inc Antikarzinomverbindungen und screeningverfahren
KR101823275B1 (ko) 2010-08-04 2018-03-08 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
AU2012260955B2 (en) * 2011-05-20 2017-08-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonists of CB1 receptor.
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
KR101352635B1 (ko) * 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
AU2013351190B2 (en) 2012-11-28 2018-03-29 Alienor Farma 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2968219B1 (de) * 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Neuartige therapie gegen prostatakarzinome
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (de) 2014-10-16 2021-04-20 Sage Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) * 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (de) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
CN107722101A (zh) * 2017-11-03 2018-02-23 郑州大学 甾体吡啶类衍生物及其制备方法和应用
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
CN111333696B (zh) * 2020-04-07 2021-09-24 华中药业股份有限公司 一种治疗痛风的化合物及其制备方法和用途
CN114344310B (zh) * 2021-12-02 2023-10-10 华中药业股份有限公司 一种治疗痛风的药物组合物及其制备方法与用途
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2335616A (en) * 1941-11-06 1943-11-30 Parke Davis & Co Steroidal hormone intermediates and their preparation
US2664423A (en) * 1952-03-12 1953-12-29 Searle & Co 4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
US2707189A (en) * 1952-09-11 1955-04-26 Upjohn Co 3-keto-17beta-acetamido-4-androstene and process
NL125073C (de) * 1961-07-24
FR1381407A (fr) * 1963-10-17 1964-12-14 Roussel Uclaf Procédé de préparation de composés tétracycliques et produits obtenus par ce procédé
US3313809A (en) * 1965-03-05 1967-04-11 Sterling Drug Inc Steroido[21, 20-d]isoxazoles
US3317520A (en) * 1965-03-05 1967-05-02 Sterling Drug Inc Steroido[20, 21-c]pyrazoles and intermediates
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
ATE195129T1 (de) * 1992-05-20 2000-08-15 Merck & Co Inc 4-azasteroide als 5-alpha-reduktase
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
WO1997014418A1 (en) * 1995-10-19 1997-04-24 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
AU6045398A (en) 1998-08-25
WO1998033506A1 (en) 1998-08-06
JP2010024238A (ja) 2010-02-04
EP1019060B1 (de) 2007-08-01
US6133280A (en) 2000-10-17
ES2290984T3 (es) 2008-02-16
CA2279971A1 (en) 1998-08-06
JP2001510471A (ja) 2001-07-31
DE69838177D1 (de) 2007-09-13
EP1019060A4 (de) 2005-04-13
ATE368466T1 (de) 2007-08-15
PT1019060E (pt) 2007-10-03
CA2279971C (en) 2011-07-12
EP1019060A1 (de) 2000-07-19
CA2628607C (en) 2011-06-07
DE69838177T2 (de) 2008-04-10
CA2628607A1 (en) 1998-08-06
US5994334A (en) 1999-11-30
JP5043250B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
ATE368466T1 (de) Androgensyntheseinhibitoren
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
CY1107862T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα οιστερολης για χρηση στη θεραπεια του καρκινου
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1107721T1 (el) Παραγωγα τυροζινης
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
AP9901478A0 (en) Compounds for the treatment of ischemia.
DE69834024D1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
EP1320376A4 (de) Behandlung von prostatakrebs
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
PT880540E (pt) 17-beta-ciclopropil-(amino/oxi)-4-azaesteroides como inibidores activos de 5-alfa-redutase e c17-c20-liase de testosterona
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2001028593A3 (en) Conjugates useful in the treatment of prostate cancer
DE3574563D1 (de) Zusammensetzungen und verbindungen zur behandlung von prostata-adenom.
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf